



EMPOWERING CONSISTENT CARE

With.

VONOHENZ

Vonoprazan 10 mg and 20 mg Tablets


VONOHENZ

Vonoprazan 10 mg and 20 mg Tablets

BACKGROUND:

- Over time, GERD has become common globally. Despite PPI treatment, many patients remain dissatisfied. Notably, H.pylori infection inversely correlates with GERD. Global prevalence of GERD is 20% and H. pylori is 50%.^{1,2,3}
- Vonoprazan (VPZ), a novel potassium-competitive acid blocker (PCAB), provides stronger, faster, and longer acid suppression than PPIs, showing superior efficacy against GERD, H. pylori, and ulcers, addressing therapy limitations.¹

MECHANISM OF ACTION OF PPIs AS COMPARED WITH P-CABS⁴:



- PPIs convert to their active form in acid milieu within the secretory canaliculi and bind covalently to H⁺/K⁺-ATPases in a stimulated parietal cell
- P-CABs accumulate in high concentrations in secretory canaliculi and bind reversibly to H⁺/K⁺-ATPases without requiring an acidic environment for activation.

VONOPRAZAN FULL & FAST EFFECT FROM FIRST DOSE⁵:




Fig. Time course of acid inhibition by P-CABs and PPIs.

CLINICAL RESEARCH

1 EFFICACY OF VONOPRAZAN FOR PROTON PUMP INHIBITOR-RESISTANT REFLUX ESOPHAGITIS (RE)⁶

Total Patients: 24 PPI-resistant RE patients

Duration: 4 Weeks

Dose: Vonoprazan 20 mg

Result:




Fig. Endoscopic healing rate of vonoprazan therapy at 20 mg for 4 weeks for proton pump inhibitor-resistant reflux esophagitis. LA: Los Angeles.

Conclusion: Vonoprazan effectively treats most PPI-resistant RE patients. Among these patients, a 4-week, 20 mg VPZ course resulted in a 90% endoscopic healing rate.

2 COMPARATIVE REVIEW OF FIRST-LINE H. PYLORI ERADICATION THERAPIES⁷

VPZ-Based Regimen		PPI-Based Regimen	
Regimen	Eradication Rate	Regimen	Eradication Rate
VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	95.8%	LPZ: 30 mg bid or RPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	69.6%
VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	95.8%	RPZ: 10 mg bid or ESO: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	72.8%

*AMX: Amoxicillin, CLR: Clarithromycin, ESO: Esomeprazole, LPZ: Lansoprazole, RPZ: Rabeprazole, VPZ: Vonoprazan.

EMPOWERING CONSISTENT CARE



VONOHENZ

Vonoprazan 10 mg and 20 mg Tablets

DESCRIPTION:

VONOHENZ tablets contain Vonoprazan, a potent inhibitor of gastric acid secretion, available in 10 mg and 20 mg strengths. Vonoprazan (VPZ) offers superior symptomatic relief through its innovative mechanism and sustained therapeutic effectiveness.

INDICATION:

- Treatment of Reflux esophagitis (RE), gastric ulcer (GU) & duodenal ulcer (DU)
- Prevention of reoccurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration/ NSAIDs administration
- Adjunct to Helicobacter pylori (H. pylori) eradication

MECHANISM OF ACTION:

Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the H⁺, K⁺-ATPase enzyme system in a potassium-competitive manner.

VONOHENZ

It suppresses basal and stimulated gastric acid secretion at the secretory surface of gastric parietal cells.

KEY FEATURES:

Faster Onset:	A faster onset of action than PPIs. ⁸
Non-Acid Activation:	Doesn't require stomach acid for effectiveness. ⁸
Meal independent:	Vonoprazan effect is not influenced by meals. ⁴
Stronger Suppression:	Provides potent and sustained inhibition of gastric acid secretion. ¹
Long Lasting Effect:	Stable and persists in the stomach, exerting a long-lasting effect. ⁸
Potassium Competitive:	Competes with potassium for proton pump binding, boosting efficacy. ⁸
Higher Efficacy:	Superior effectiveness in treating conditions like GERD and H. pylori infection compared to PPIs. ^{1,6}
Reduced Resistance:	Suitable alternative for patients with PPI resistance or intolerance. ⁶

DOSAGE:

The recommended dose of vonoprazan is 10-20 mg OD or as suggested by the healthcare professional.

PRESENTATION:

VONOHENZ-10/20 available as a strip of 10 tablets.

REFERENCES:

1. Kang et al. *Medicine* (2018) 97:39. | 2. *Ann Esophagus* 2022;5:7 | 3. Misra V et. al. *World Journal of Gastroenterology: WJG*. 2014 Feb 2;20(6):1503 | 4. *Gastroenterology Review* 2023; 18 (1) | 5. *Pharmaceuticals* 2020, 13, 276 | 6. *Intern Med* 56: 1277-1285, 2017 | 7. *Intern Med* 57: 2443-2450, 2018 | 8. *Journal of Gastroenterology*. 2020 Nov;55:1054-61.

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

Scan for more
Prescribing Information



I am: _____
Call me on: _____
Mail me at: _____

©2024 All rights reserved, La Renon Healthcare Private Limited